Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ. O'Farrell AM, et al. Among authors: lancet je. Leuk Res. 2004 Jul;28(7):679-89. doi: 10.1016/j.leukres.2003.11.004. Leuk Res. 2004. PMID: 15158089 Clinical Trial.
Acute myeloid leukemia clinical practice guidelines in oncology.
O'Donnell MR, Appelbaum FR, Baer MR, Byrd JC, Coutre SE, Damon LE, Erba HP, Estey E, Foran J, Lancet J, Maness LJ, Maslak PG, Millenson M, Moore JO, Przepiorka D, Shami P, Smith BD, Stone RM, Tallman MS. O'Donnell MR, et al. J Natl Compr Canc Netw. 2006 Jan;4(1):16-36. doi: 10.6004/jnccn.2006.0004. J Natl Compr Canc Netw. 2006. PMID: 16403402 No abstract available.
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. Lancet JE, et al. Blood. 2007 Feb 15;109(4):1387-94. doi: 10.1182/blood-2006-04-014357. Epub 2006 Nov 2. Blood. 2007. PMID: 17082323 Free PMC article. Clinical Trial.
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.
Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Kharfan-Dabaja MA, et al. Biol Blood Marrow Transplant. 2011 Mar;17(3):384-93. doi: 10.1016/j.bbmt.2010.07.011. Epub 2010 Jul 22. Biol Blood Marrow Transplant. 2011. PMID: 20655389 Free article.
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. Lancet JE, et al. Clin Cancer Res. 2011 Mar 1;17(5):1140-6. doi: 10.1158/1078-0432.CCR-10-1878. Epub 2011 Jan 13. Clin Cancer Res. 2011. PMID: 21233404 Free PMC article. Clinical Trial.
228 results